Medigene to Present at the Cell and Gene Therapy In-Depth Focus Summit 2024
June 21 2024 - 4:30AM
Planegg/Martinsried, June 21,
2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime
Standard), an immuno-oncology platform company focusing on the
discovery and development of T cell immunotherapies for solid
tumors, will present virtually at the 7th Cell and Gene Therapy
In-Depth Focus Summit taking place from June 27-28, 2024, in
Beijing, China.
The presentation will be available on Medigene´s
website following the conference:
https://medigene.com/science/abstracts/
Virtual presentation:
7th Cell and Gene Therapy In-Depth Focus Summit
2024https://www.bagevent.com/event/8751058Location: Crown Hotel
Youtang, Beijing, China (virtual presentation)Date and time: June
27, 2024; 4.30 – 5pm local timePresenter: Kirsty Crame, MD, VP
Clinical Strategy & DevelopmentTitle: MDG1015: a 3rd
Generation TCR-T Therapy Incorporating the PD1-41BB Costimulatory
Switch Protein, Advancing to the Clinic
The presentation will feature the Company's lead
program MDG1015, a first-in-class third-generation T cell
receptor-engineered T cell (TCR-T) therapy. This therapy targets
NY-ESO-1/LAGE-1a (New York oesophageal squamous cell carcinoma 1 /
L Antigen Family Member-1a) and is enhanced with the PD1-41BB
costimulatory switch protein. The first-in-human trial for MDG1015
is planned for gastric cancer, ovarian cancer, myxoid/round cell
liposarcoma, and synovial sarcoma, and is on track for
Investigational New Drug (IND) filing in Q3 2024 and Clinical Trial
Application (CTA) filing in Q4 2024.
--- end of press release ---
About Medigene AG
Medigene AG (FSE: MDG1) is an immuno-oncology
platform company dedicated to developing differentiated T cell
therapies for treatment of solid tumors. Its End-to-End Platform is
built on multiple proprietary and exclusive technologies that
enable the Company to generate optimal T cell receptors against
both cancer testis antigens and neoantigens, armor and enhance
these T cell receptor engineered (TCR) -T cells to create
best-in-class, differentiated TCR-T therapies, and optimize the
drug product composition for safety, efficacy and durability. The
End-to-End Platform provides product candidates for both its own
therapeutics pipeline and partnering. Medigene’s lead TCR-T program
MDG1015 is on track for IND filing in Q3 2024 and CTA filing in Q4
2024. For more information, please visit https://medigene.com/
This press release contains forward-looking
statements representing the opinion of Medigene as of the date of
this release. The actual results achieved by Medigene may differ
significantly from the forward-looking statements made herein.
Medigene is not bound to update any of these forward-looking
statements. Medigene® is a registered trademark of Medigene AG.
This trademark may be owned or licensed in select locations
only.
Medigene AGPamela KeckPhone: +49 89 2000
3333 01E-mail: investor@medigene.com
In case you no longer wish to receive any
information about Medigene, please inform us by e-mail
(investor@medigene.com). We will then delete your address from our
distribution list.